On December 23, 2014, the FDA approved liraglutide, under the name Saxenda, to treat obesity, after having previously approved it under the name Victoza to treat type 2 diabetes mellitus (T2DM).
As Saxenda, the glucagon-like peptide-1 (GLP-1) receptor agonist will be approved for adults with a body mass index (BMI) of 30 or higher, or for adults with a BMI of 27 or higher plus at least 1 other comorbidity, such as T2DM or high cholesterol. The FDA specifically warned against patients taking any other GLP-1 drugs along with Saxenda, including Victoza.1
While the 2 drugs contain the same active ingredient, the approved dose for Saxenda is higher, at 3 mg, than for Victoza, at 1.8 mg.1 The approval for Saxenda (liraglutide [rDNA origin] injection) is based on results from a clinical trial that enrolled patients without diabetes, which showed that patients had an average weight loss of 4.5% from baseline compared with those receiving
placebo for 1 year. In the trial, 62% of patients treated with Saxenda lost at least 5% of their body weight compared with 34% of those treated with placebo.
In another clinical trial, at the 1-year mark, patients with T2DM had an average weight loss of 3.7% from baseline compared with those receiving placebo. In this trial, 49% of patients treated with Saxenda lost at least 5% of their body weight compared with 16% of patients treated with placebo.
In a statement, the FDA said patients who receive Saxenda should be evaluated after 16 weeks to see if the drug is working, and the drug should be stopped if a patient has not lost at least 4% of
baseline body weight. Saxenda has a boxed warning stating that tumors of the thyroid gland have been observed in studies with rodents, but that it is unknown whether the drug causes thyroid tumors in humans. Persons with a family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia syndrome type 2 should not take the drug. The FDA also ordered several post marketing studies for Saxenda. Common side effects were nausea, diarrhea, constipation, vomiting, low blood sugar, and decreased appetite.1
In a statement, manufacturer Novo Nordisk said Saxenda will be launched in the first half of 2015. “Many people suffer from comorbidities. Saxenda has the potential to help some of those people
achieve and maintain a clinically significant weight loss and improve their weight-related comorbidities,” said Mads Krogssgaard Thomsen, executive vice president and chief science officer.2
References
1. FDA approves weight management drug
Saxenda [press release]. Silver Spring, MD: FDA
Newsroom; December 23, 2014. http://www
.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm427913.htm.
2. Novo Nordisk receives FDA approval for
Saxenda® (liraglutide [rDNA origin] injection)
for chronic weight management [press release].
Plainsboro, NJ: PR Newswire; December 24,
2014. http://press.novonordisk-us.com/index
.php?s=20295&item=122801.
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Inspiring Clinicians to Take Action on Closing Diabetes Care Gaps
December 7th 2023Clinicians and leaders from Duke University convened in Durham, North Carolina, to discuss unmet needs in the care of patients with diabetes and opportunities to close those gaps through coordination, education, support, and technology.
Read More
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
Exclusive Telemedicine Use Linked to Less Favorable Glycemic Outcomes for T2D Endocrinology Care
December 6th 2023Adults with type 2 diabetes (T2D) undergoing endocrinology care are more likely to experience less favorable hemoglobin A1c improvements if they only use telemedicine compared with patients using in-person care or a mix of both.
Read More